Obesity is a chronic disease associated with serious complications and increased mortality. Until recently, bariatric surgery was the only intervention that consistently resulted in ≥15% WL and maintenance. Our better understanding of the role of gut-brain axis on appetite regulation has led to the development over the last years of safe and effective medications for obesity management which are based on entero-pancreatic hormones, such as glucagon-like peptide-1 (GLP-1) receptor analogues (RAs). Semaglutide 2.4 mg once weekly is the latest approved GLP-1 RA for chronic weight management leading to 15-17% weight loss with evidence of cardioprotection. Moreover, the WL achieved with the dual agonist tirzepatide (GLP-1/glucose-dependent insulinotropic polypeptide) for people with type 2 diabetes and most recently also obesity, indicate that combining the GLP-1 with other gut hormones may lead to additional WL compared with GLP-1 receptor analogues alone and in the future, multi-agonist molecules may offer the potential to bridge further the efficacy gap between bariatric surgery and the currently available pharmacotherapies. The evidence behind the medications approved by NICE for obesity management, as well as the NICE criteria for their prescription will be discussed in this session.